Dechert advised Ablynx (Belgium-based) on the licensing agreement with Eddingpharm (a Chinese specialty pharmaceutical company) regarding the development, manufacturing and commercialization of ALX-0141 in China. ALX-0141 is a candidate Nanobody for treating bone-loss related disorders, including osteoporosis and bone metastases and successfully completed a Phase I study in post-menopausal women. In connection with the license agreement, Dechert also advised Ablynx on China-specific aspects of the agreement, including tax arrangements, regulatory approvals, IP ownership, technology transfer requirements and other compliance issues; conducting independent due diligence against company structure, financial and compliance record of the potential partners in China.

The Dechert team advising Ablynx includes Hong Kong-based partner Lewis Ho as well as U.S.-based partners Daniel Becker and David Schulman.